Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
Scientists identified mechanisms of TNBC resistance to Sacituzumab Govitecan through RNA and whole-exome sequencing of pre-treatment and post-progression specimens.